WebMD1d
FDA OKs Triple Combo for Advanced Large B-Cell Lymphoma
The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).
Oncology Nurse Advisor1d
CD70-Directed CAR-T Therapy Shows Promise in T-Cell Lymphoma
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Armed robbery in Revesby1d
FDA OKs Pfizer's ADCETRIS Combo for Relapsed Lymphoma
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...
BioSpace1d
Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
PipelineReview.com1d
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NEW YORK, NY, USA I 12, 2025 I Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
The Sign Your Common Cold Could Be A Deadly Cancer; Know Other Symptoms of Lymphoma
This is the cold season, and many people are down with runny nose, fever, cough, and tiredness. However, according to experts ...
Cancer Therapy Advisor1d
Adcetris Combo Approved for Rel/Ref Large B-Cell Lymphoma
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...